Faculty of Nursing, Manchester Metropolitan University
In the UK vaccination programme, HPV vaccination is predominantly promoted as a female public health concern, and vaccination is aimed at girls aged 12–13 years old. Recent studies in HPV vaccination have shown health benefits for males in the prevention of ano-genital and penile cancer and genital warts. The purpose of this article is to highlight the key aspects of, and what influences, HPV vaccination uptake in males. Moreover, light is shed on areas not covered by a binary male vs. female approach to vaccinations, such as vaccination of men who have sex with men and people with HIV. Key influences include public awareness, vaccination cost and recommendations from health care professionals (HCPs). Despite male vaccination being supported by significant national and international organisations, in the UK it remains a thorny issue which needs an up-to-date discussion and a potential review of clinical practice.